• Je něco špatně v tomto záznamu ?

MRP4 is responsible for the efflux transport of mycophenolic acid β-d glucuronide (MPAG) from hepatocytes to blood

J. Berthier, M. Benmameri, FL. Sauvage, G. Fabre, B. Chantemargue, H. Arnion, P. Marquet, P. Trouillas, N. Picard, F. Saint-Marcoux,

. 2021 ; 51 (1) : 105-114. [pub] 20200906

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20027574

Mycophenolic acid (MPA) has become a cornerstone of immunosuppressive therapy, in particular for transplant patients. In the gastrointestinal tract, the liver and the kidney, MPA is mainly metabolized into phenyl-β-d glucuronide (MPAG). Knowledge about the interactions between MPA/MPAG and membrane transporters is still fragmented. The aim of the present study was to explore these interactions with the basolateral hepatic MRP4 transporter. The inhibition of the MRP4-driven transport by various drugs which can be concomitantly prescribed was also evaluated. In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 ± 32.8 µM). MPA was not effluxed by MRP4. MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin. An in silico approach based on molecular docking and molecular dynamics simulations rationalized the mode of binding of MPAG to MRP4. The presence of the glucuronide moiety in MPAG was highlighted as key, being prone to make electrostatic and H-bond interactions with specific residues of the MRP4 protein chamber. This explains why MPAG is a substrate of MRP4 whereas MPA is not.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027574
003      
CZ-PrNML
005      
20210114152109.0
007      
ta
008      
210105s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00498254.2020.1813352 $2 doi
035    __
$a (PubMed)32820679
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Berthier, Joseph $u INSERM, UMR 1248, Univ. Limoges, Limoges, France. CHU Limoges, Service de Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France.
245    10
$a MRP4 is responsible for the efflux transport of mycophenolic acid β-d glucuronide (MPAG) from hepatocytes to blood / $c J. Berthier, M. Benmameri, FL. Sauvage, G. Fabre, B. Chantemargue, H. Arnion, P. Marquet, P. Trouillas, N. Picard, F. Saint-Marcoux,
520    9_
$a Mycophenolic acid (MPA) has become a cornerstone of immunosuppressive therapy, in particular for transplant patients. In the gastrointestinal tract, the liver and the kidney, MPA is mainly metabolized into phenyl-β-d glucuronide (MPAG). Knowledge about the interactions between MPA/MPAG and membrane transporters is still fragmented. The aim of the present study was to explore these interactions with the basolateral hepatic MRP4 transporter. The inhibition of the MRP4-driven transport by various drugs which can be concomitantly prescribed was also evaluated. In vitro experiments using vesicles overexpressing MRP4 showed an ATP-dependent transport of MPAG driven by MRP4 (Michaelis-Menten constant of 233.9 ± 32.8 µM). MPA was not effluxed by MRP4. MRP4-mediated transport of MPAG was inhibited (from -43% to -84%) by ibuprofen, cefazolin, cefotaxime and micafungin. An in silico approach based on molecular docking and molecular dynamics simulations rationalized the mode of binding of MPAG to MRP4. The presence of the glucuronide moiety in MPAG was highlighted as key, being prone to make electrostatic and H-bond interactions with specific residues of the MRP4 protein chamber. This explains why MPAG is a substrate of MRP4 whereas MPA is not.
650    _2
$a biologický transport $7 D001692
650    _2
$a glukuronidy $x metabolismus $7 D020719
650    _2
$a hepatocyty $x metabolismus $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x metabolismus $7 D007668
650    _2
$a játra $x metabolismus $7 D008099
650    _2
$a membránové transportní proteiny $x metabolismus $7 D026901
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a proteiny spojené s mnohočetnou rezistencí k lékům $x metabolismus $7 D027425
650    _2
$a kyselina mykofenolová $x analogy a deriváty $x metabolismus $7 D009173
655    _2
$a časopisecké články $7 D016428
700    1_
$a Benmameri, Mehdi $u INSERM, UMR 1248, Univ. Limoges, Limoges, France.
700    1_
$a Sauvage, François-Ludovic $u INSERM, UMR 1248, Univ. Limoges, Limoges, France.
700    1_
$a Fabre, Gabin $u INSERM, UMR 1248, Univ. Limoges, Limoges, France.
700    1_
$a Chantemargue, Benjamin $u INSILIBIO, Limoges, France.
700    1_
$a Arnion, Hélène $u INSERM, UMR 1248, Univ. Limoges, Limoges, France.
700    1_
$a Marquet, Pierre $u INSERM, UMR 1248, Univ. Limoges, Limoges, France. CHU Limoges, Service de Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France.
700    1_
$a Trouillas, Patrick $u INSERM, UMR 1248, Univ. Limoges, Limoges, France. RCPTM, Univ. Palacký of Olomouc, Olomouc, Czech Republic.
700    1_
$a Picard, Nicolas $u INSERM, UMR 1248, Univ. Limoges, Limoges, France. CHU Limoges, Service de Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France.
700    1_
$a Saint-Marcoux, Franck $u INSERM, UMR 1248, Univ. Limoges, Limoges, France. CHU Limoges, Service de Pharmacologie, Toxicologie et Pharmacovigilance, Limoges, France.
773    0_
$w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 51, č. 1 (2021), s. 105-114
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32820679 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152107 $b ABA008
999    __
$a ok $b bmc $g 1607909 $s 1118754
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 51 $c 1 $d 105-114 $e 20200906 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

    Možnosti archivace